Adocia

117 articles with Adocia

• 

  Clinical Catch-Up: Adocia, Allecra and Aldeyra

  10/6/2022

  ​​​​​​​Adocia, Allecra Therapeutics and Aldeyra Therapeutics announced promising results in Type I Diabetes, urinary tract infections and retinal diseases.  
• 

  Global Roundup: RDIF Touts Efficacy of Sputnik V in HIV Patients

  3/31/2022

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Adocia strengthens its cash position by 19 million euros following a real estate transaction

  3/28/2022

  Adocia, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced the completion of the sale of its laboratory and office complex located in Lyon, France to a specialized investor.

• Adocia announces 2021 fourth quarter financial results

  2/23/2022

  Adocia, a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced its fourth quarter financial results.

• 

  Clinical Catch-Up: October 11-15

  10/18/2021

  It was yet another busy week for clinical trial announcements. Take a look.

• Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

  10/14/2021

  Adocia announced that its partner Tonghua Dongbao Pharmaceutical Co. Ltd. received clearance from the Center for Drug Evaluation of the China National Medical Products Administration to conduct the Phase 3 clinical trial of BioChaperone® Lispro, an Ultra-Rapid Insulin for the treatment of Type 1 and Type 2 diabetes.

• Adocia to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

  9/10/2021

  Adocia announced that Gerard Soula, Adocia’s CEO, will be presenting at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place from September 13 to 15, 2021.

• Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

  6/29/2021

  Adocia (Euronext Paris: FR0011184241 – ADOC), announced today the launch of a Phase 1 clinical study in collaboration with Dr. Ahmad Haidar, McGill University, Canada, to assess pharmacokinetic, glycemic control and safety of BioChaperone® Lispro Pramlintide (BC LisPram) prandial formulation in 16 people with type 1 diabetes compared to rapid insulin lispro.

• ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81ˢᵗ Scientific Sessions

  6/15/2021

  ADOCIA announced Adocia will have an oral presentation on the bi-hormonal treatment M1Pram at the 81st Scientific Sessions of the American Diabetes Association which will be held June 25-29, 2021, as a virtual event.

• Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

  5/26/2021

  Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity treatment

• Adocia announces first quarter 2020 financial results and update on the impact of COVID-19

  4/17/2020

  ADOCIA (Euronext Paris: FR0011184241 – ADOC the “Company”and “Adocia”), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announced today its financial results, including revenue and cash position, for the quarter ended March 31st, 2020.

• Adocia announces its financial calendar for 2020

  12/17/2019

  Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of approved proteins, announced its financial calendar for 2020.

• Adocia Announces Third Quarter 2019 Financial Results

  10/22/2019

  Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced third quarter revenue and net cash position as of September 30, 2019.

• Adocia obtains additional financial resources to accelerate its growth

  10/14/2019

  Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners

• Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case

  9/30/2019

  The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly

• Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)

  9/10/2019

  Adocia announced that it will deliver an oral presentation covering its ADO09 product at the 55th Annual Meeting of the European Association for the Study of Diabetes, being held September 16-20, 2019 in Barcelona, Spain.

• Adocia Announces that the American Arbitration Association Tribunal Dismissed All Claims in Second Phase of Arbitration with Eli Lilly

  8/23/2019

  Adocia announced that the American Arbitration Association Tribunal governing Adocia’s arbitration claims against Eli Lilly & Company dismissed both parties’ claims in the second and final phase of the arbitration between Adocia and Lilly.

• 

  Eli Lilly Wins Arbitration Hearing Against Adocia

  8/23/2019

  Eli Lilly won an arbitration hearing over accusations the Indianapolis-based company misused confidential information regarding the intellectual property of its former business partner, France-based Adocia S.A.

• Arbitration panel rules in favor of Lilly in complaint filed by Adocia

  8/22/2019

  The panel of three arbitrators ruled that Lilly acted appropriately regarding Adocia's intellectual property, and while they denied Lilly's smaller counterclaim, ruled that Lilly is not liable for damages.

• Adocia Presents First Half 2019 Financial Results

  7/17/2019

  Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.